Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy

Cancer Treatment Reviews

Volumn 33, Issue 2, 2007, Pages 191-202

  Vink, Stefan R ^a   van Blitterswijk, Wim J ^a   Schellens, Jan H M ^a   Verheij, Marcel ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

(Pre) clinical; Alkylphospholipids; Apoptosis; PKB Akt; Radiotherapy; Signal transduction

Indexed keywords

BM 41 440; DNA; EDELFOSINE; ERUCYLPHOSPHOCHOLINE; ILMOFOSINE; MILTEFOSINE; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPID DERIVATIVE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRITIS; BONE MARROW PURGING; BRAIN CANCER; BREAST CARCINOMA; CANCER CELL; CANCER RADIOTHERAPY; CANCER REGRESSION; CELL DEATH; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CYTOTOXICITY; DIARRHEA; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL DISEASE; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; HYPERURICEMIA; HYPONATREMIA; INHIBITION KINETICS; KIDNEY CARCINOMA; LEISHMANIASIS; LIPID METABOLISM; LIPOGENESIS; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; MELANOMA; NAUSEA AND VOMITING; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; SIGNAL TRANSDUCTION; SKIN LYMPHOMA; SKIN METASTASIS; SOFT TISSUE SARCOMA; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; PHOSPHOLIPID ETHERS; PHOSPHORYLCHOLINE;

EID: 33847289770     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.12.001     Document Type: Review

References (132)

1. Haas R.L., Poortmans P., de Jong D., et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 21 (2003) 2474-2480
2. Lawrence T.S., Blackstock A.W., and McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 13 (2003) 13-21
3. Bartelink H., Schellens J.H., and Verheij M. The combined use of radiotherapy and chemotherapy in the treatment of solid tumours. Eur J Cancer 38 (2002) 216-222
4. Ma B.B., Bristow R.G., Kim J., et al. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 21 (2003) 2760-2776
5. Belka C., Jendrossek V., Pruschy M., et al. Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int J Radiat Oncol Biol Phys 58 (2004) 542-554
6. Munder P.G., Modolell M., Andreesen R., et al. Lysophosphatidylcholine (lysolecithin) and its synthetic analogues. Immunomodulating and other biologic effects. Immunopathology 2 (1979) 187-203
7. Runge M.H., Andreesen R., Pfleiderer A., et al. Destruction of human solid tumors by alkyl lysophospholipids. J Natl Cancer Inst 64 (1980) 1301-1306
8. Berdel W.E., Bausert W.R., Weltzien H.U., et al. The influence of alkyl-lysophospholipids and lysophospholipid-activated macrophages on the development of metastasis of 3-Lewis lung carcinoma. Eur J Cancer 16 (1980) 1199-1204
9. Tarnowski G.S., Mountain I.M., Stock C.C., et al. Effect of lysolecithin and analogs on mouse ascites tumors. Cancer Res 38 (1978) 339-344
10. Berger M.R., Munder P.G., Schmahl D., et al. Influence of the alkyllysophospholipid ET-18-OCH3 on methylnitrosourea-induced rat mammary carcinomas. Oncology 41 (1984) 109-113
11. Scherf H.R., Schuler B., Berger M.R., et al. Therapeutic activity of ET-18-OCH3 and hexadecylphosphocholine against mammary tumors in BD-VI rats. Lipids 22 (1987) 927-929
12. Berdel W.E., Fink U., and Rastetter J. Clinical phase I pilot study of the alkyl lysophospholipid derivative ET-18-OCH3. Lipids 22 (1987) 967-969
13. Khanavkar B., Ulbrich F., Gatzemeier U., et al. Treatment of non-small cell lung cancer with the alkyllysophospholipid edelfosine. Contrib Oncol 37 (1989) 224-235
14. Vogler W.R., Olson A.C., Okamoto S., et al. Experimental studies on the role of alkyl lysophospholipids in autologous bone marrow transplantation. Lipids 22 (1987) 919-924
15. Vogler W.R., Berdel W.E., Olson A.C., et al. Autologous bone marrow transplantation in acute leukemia with marrow purged with alkyl-lysophospholipid. Blood 80 (1992) 1423-1429
16. Vogler W.R., Berdel W.E., Geller R.B., et al. A phase II trial of autologous bone marrow transplantation (ABMT) in acute leukemia with edelfosine purged bone marrow. Adv Exp Med Biol 416 (1996) 389-396
17. Andreesen R., Modolell M., Weltzien H.U., et al. Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer Res 38 (1978) 3894-3899
18. Berdel W.E., Fromm M., Fink U., et al. Cytotoxicity of thioether-lysophospholipids in leukemias and tumors of human origin. Cancer Res 43 (1983) 5538-5543
19. Neumann H.A., Herrmann D.B., and Boerner D. Inhibition of human tumor colony formation by the new alkyl lysophospholipid ilmofosine. J Natl Cancer Inst 78 (1987) 1087-1093
20. Herrmann D.B., Opitz H.G., and Munder P.G. Antitumor activity of Ilmofosine (BM 41.440) in the 3Lewis-lung carcinoma model. Lipids 26 (1991) 1431-1436
21. Girgert R., Schweizer P., Bock I., et al. Cytotoxicity of ether phospholipid BM 41.440 on neuroblastoma cells. J Cancer Res Clin Oncol 121 (1995) 262-266
22. Skala J.P., Rogers P.C., Chan K.W., et al. In vitro effects of Ilmofosine on acute lymphoblastic leukemia cells and on normal hemopoietic cells. Prog Clin Biol Res 377 (1992) 63-69
23. Hanauske A.R., Degen D., Marshall M.H., et al. Preclinical activity of ilmofosine against human tumor colony forming units in vitro. Anticancer Drugs 3 (1992) 43-46
24. Herrmann D.B., Pahlke W., Opitz H.G., et al. In vivo antitumor activity of ilmofosine. Cancer Treat Rev 17 (1990) 247-252
25. von Mehren M., Giantonio B.J., McAleer C., et al. Phase I trial of ilmofosine as a 24 hour infusion weekly. Invest New Drugs 13 (1995) 205-210
26. Giantonio B.J., Derry C., McAleer C., et al. Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors. Clin Cancer Res 10 (2004) 1282-1288
27. Woolley P.V., Schultz C.J., Rodriguez G.I., et al. A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma. Invest New Drugs 14 (1996) 219-222
28. Hilgard P., Klenner T., Stekar J., et al. Alkylphosphocholines: a new class of membrane-active anticancer agents. Cancer Chemother Pharmacol 32 (1993) 90-95
29. Breiser A., Kim D.J., Fleer E.A., et al. Distribution and metabolism of hexadecylphosphocholine in mice. Lipids 22 (1987) 925-926
30. Unger C., Damenz W., Fleer E.A., et al. Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. Acta Oncol 28 (1989) 213-217
31. Yanapirut P., Berger M.R., Reinhardt M., et al. In vitro investigations on the antineoplastic effect of hexadecylphosphocholine. Arzneimittelforschung 41 (1991) 652-655
32. Ries U.J., Fleer E.A., Breiser A., et al. In vitro and in vivo antitumoral activity of alkylphosphonates. Eur J Cancer 29A (1992) 96-101
33. Wang Y.Z., Liu X.Y., Wu L.J., et al. Antiproliferation effects of hexadecylphosphocholine on solid tumour and leukaemia selectively in vitro. Drugs Exp Clin Res 23 (1997) 97-102
34. Hilgard P., Stekar J., Voegeli R., et al. Experimental therapeutic studies with miltefosine in rats and mice. Prog Exp Tumor Res 34 (1992) 116-130
35. Hilgard P., Stekar J., Voegeli R., et al. Characterization of the antitumor activity of hexadecylphosphocholine (D 18506). Eur J Cancer Clin Oncol 24 (1988) 1457-1461
36. Berger M.R., Muschiol C., Schmahl D., et al. New cytostatics with experimentally different toxic profiles. Cancer Treat Rev 14 (1987) 307-317
37. Kotting J., Marschner N.W., Neumuller W., et al. Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution. Prog Exp Tumor Res 34 (1992) 131-142
38. Verweij J., Krzemieniecki K., Kok T., et al. Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult - an EORTC Soft Tissue and Bone Sarcoma Group Study. Eur J Cancer 29A (1993) 208-209
39. Planting A.S., Stoter G., and Verweij J. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur J Cancer 29A (1993) 518-519
40. Verweij J., Gandia D., Planting A.S., et al. Phase II study of oral miltefosine in patients with squamous cell head and neck cancer. Eur J Cancer 29A (1993) 778-779
41. Unger C., Peukert M., Sindermann H., et al. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Cancer Treat Rev 17 (1990) 243-246
42. Dummer R., Krasovec M., Roger J., et al. Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study. J Am Acad Dermatol 29 (1993) 963-970
43. Terwogt J.M., Mandjes I.A., Sindermann H., et al. Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. Br J Cancer 79 (1999) 1158-1161
44. Leonard R., Hardy J., van Tienhoven G., et al. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol 19 (2001) 4150-4159
45. Croft S.L., Seifert K., and Duchene M. Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol 126 (2003) 165-172
46. Berman J.D. Development of miltefosine for the leishmaniases. Mini Rev Med Chem 6 (2006) 145-151
47. Hilgard P., Stekar J., Klenner T., et al. Heterocyclic alkylphospholipids with an improved therapeutic range. Adv Exp Med Biol 416 (1996) 157-164
48. Vink S.R., Schellens J.H., van Blitterswijk W.J., et al. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid. Invest New Drugs 23 (2005) 279-286
49. Hilgard P., Klenner T., Stekar J., et al. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 33 (1997) 442-446
50. Crul M., Rosing H., de Klerk G.J., et al. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 38 (2002) 1615-1621
51. Van Ummersen L., Binger K., Volkman J., et al. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 10 (2004) 7450-7456
52. Ernst D.S., Eisenhauer E., Wainman N., et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 23 (2005) 1-7
53. Posadas E.M., Gulley J., Arlen P.M., et al. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 4 (2005) 1133-1137
54. Knowling M., Blackstein M., Tozer R., et al. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 24 (2006) 435-439
55. Argiris A., Cohen E., Karrison T., et al. A Phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther (2006) 5
56. Kaufmann-Kolle P., Berger M.R., Unger C., et al. Systemic administration of alkylphosphocholines. Erucylphosphocholine and liposomal hexadecylphosphocholine. Adv Exp Med Biol 416 (1996) 165-168
57. Berger M.R., Sobottka S., Konstantinov S.M., et al. Erucylphospocholine is the prototype of i.v. injectable alkylphosphocholines. Drugs Today 34 (1998) 73-81
58. Erdlenbruch B., Jendrossek V., Gerriets A., et al. Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. Cancer Chemother Pharmacol 44 (1999) 484-490
59. Erdlenbruch B., Jendrossek V., Marx M., et al. Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo. Anticancer Res 18 (1998) 2551-2557
60. Jendrossek V., Erdlenbruch B., Hunold A., et al. Erucylphosphocholine, a novel antineoplastic ether lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro. Int J Oncol 14 (1999) 15-22
61. Boggs K.P., Rock C.O., and Jackowski S. Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP:phosphocholine cytidylyltransferase step. J Biol Chem 270 (1995) 7757-7764
62. Kent C. Eukaryotic phospholipid biosynthesis. Annu Rev Biochem 64 (1995) 315-343
63. Tronchere H., Record M., Terce F., et al. Phosphatidylcholine cycle and regulation of phosphatidylcholine biosynthesis by enzyme translocation. Biochim Biophys Acta 1212 (1994) 137-151
64. Boggs K.P., Rock C.O., and Jackowski S. Lysophosphatidylcholine attenuates the cytotoxic effects of the antineoplastic phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. J Biol Chem 270 (1995) 11612-11618
65. van der Luit A.H., Budde M., Verheij M., et al. Different modes of internalization of apoptotic alkyl-lysophospholipid and cell-rescuing lysophosphatidylcholine. Biochem J 374 (2003) 747-758
66. van der Sanden M.H., Houweling M., Duijsings D., et al. Inhibition of phosphatidylcholine synthesis is not the primary pathway in hexadecylphosphocholine-induced apoptosis. Biochim Biophys Acta 1636 (2004) 99-107
67. Maly K., Uberall F., Schubert C., et al. Interference of new alkylphospholipid analogues with mitogenic signal transduction. Anticancer Drug Des 10 (1995) 411-425
68. Wieder T., Zhang Z., Geilen C.C., et al. The antitumor phospholipid analog, hexadecylphosphocholine, activates cellular phospholipase D. Cancer Lett 100 (1996) 71-79
69. Lucas L., Hernandez-Alcoceba R., Penalva V., et al. Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity. Oncogene 20 (2001) 1110-1117
70. Mollinedo F., Fernandez-Luna J.L., Gajate C., et al. Selective induction of apoptosis in cancer cells by the ether lipid ET- 18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Cancer Res 57 (1997) 1320-1328
71. Kidd V.J. Proteolytic activities that mediate apoptosis. Annu Rev Physiol 60 (1998) 533-573
72. Thornberry N.A., and Lazebnik Y. Caspases: enemies within. Science 281 (1998) 1312-1316
73. Cohen G.M. Caspases: the executioners of apoptosis. Biochem J 326 Pt 1 (1997) 1-16
74. Reed J.C. Mechanisms of apoptosis. Am J Pathol 157 (2000) 1415-1430
75. Peter M.E., and Krammer P.H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 10 (2003) 26-35
76. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
77. Antonsson B., and Martinou J.C. The Bcl-2 protein family. Exp Cell Res 256 (2000) 50-57
78. Gajate C., Fonteriz R.I., Cabaner C., et al. Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int J Cancer 85 (2000) 674-682
79. Gajate C., and Mollinedo F. The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 98 (2001) 3860-3863
80. Oberle C., Massing U., and Krug H.F. On the mechanism of alkylphosphocholine (APC)-induced apoptosis in tumour cells. Biol Chem 386 (2005) 237-245
81. Cuvillier O., Mayhew E., Janoff A.S., et al. Liposomal ET-18-OCH(3) induces cytochrome c-mediated apoptosis independently of CD95 (APO-1/Fas) signaling. Blood 94 (1999) 3583-3592
82. Kugler W., Erdlenbruch B., Junemann A., et al. Erucylphosphocholine-induced apoptosis in glioma cells: involvement of death receptor signalling and caspase activation. J Neurochem 82 (2002) 1160-1170
83. Jendrossek V., Muller I., Eibl H., et al. Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene 22 (2003) 2621-2631
84. Gajate C., Santos-Beneit A.M., Macho A., et al. Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells. Int J Cancer 86 (2000) 208-218
85. Jendrossek V., Kugler W., Erdlenbruch B., et al. Erucylphosphocholine-induced apoptosis in chemoresistant glioblastoma cell lines: involvement of caspase activation and mitochondrial alterations. Anticancer Res 21 (2001) 3389-3396
86. Testa J.R., and Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98 (2001) 10983-10985
87. Alessi D.R., James S.R., Downes C.P., et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7 (1997) 261-269
88. Chan T.O., Rittenhouse S.E., and Tsichlis P.N. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 68 (1999) 965-1014
89. Datta S.R., Dudek H., Tao X., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
90. Brunet A., Bonni A., Zigmond M.J., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 (1999) 857-868
91. Romashkova J.A., and Makarov S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401 (1999) 86-90
92. Aoki M., Batista O., Bellacosa A., et al. The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci USA 95 (1998) 14950-14955
93. Mende I., Malstrom S., Tsichlis P.N., et al. Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene 20 (2001) 4419-4423
94. Nakamura J.L., Karlsson A., Arvold N.D., et al. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J Neurooncol 71 (2005) 215-222
95. Caron R.W., Yacoub A., Li M., et al. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol Cancer Ther 4 (2005) 257-270
96. Gottschalk A.R., Doan A., Nakamura J.L., et al. Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism. Int J Radiat Oncol Biol Phys 63 (2005) 1221-1227
97. Soderlund K., Perez-Tenorio G., and Stal O. Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells. Int J Oncol 26 (2005) 25-32
98. Baumann M., and Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 72 (2004) 257-266
99. Zhan M., and Han Z.C. Phosphatidylinositide 3-kinase/AKT in radiation responses. Histol Histopathol 19 (2004) 915-923
100. Kim I.A., Bae S.S., Fernandes A., et al. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 65 (2005) 7902-7910
101. Ruiter G.A., Zerp S.F., Bartelink H., et al. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 14 (2003) 167-173
102. Kondapaka S.B., Singh S.S., Dasmahapatra G.P., et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2 (2003) 1093-1103
103. Blenis J. Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci USA 90 (1993) 5889-5892
104. von Gise A., Lorenz P., Wellbrock C., et al. Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. Mol Cell Biol 21 (2001) 2324-2336
105. Zhou X., Lu X., Richard C., et al. 1-O-octadecyl-2-O-methyl-glycerophosphocholine inhibits the transduction of growth signals via the MAPK cascade in cultured MCF-7 cells. J Clin Invest 98 (1996) 937-944
106. Ruiter G.A., Zerp S.F., Bartelink H., et al. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res 59 (1999) 2457-2463
107. Samadder P., Richards C., Bittman R., et al. The antitumor ether lipid 1-Q-octadecyl-2-O-methyl-rac-glycerophosphocholine (ET-18-OCH3) inhibits the association between Ras and Raf-1. Anticancer Res 23 (2003) 2291-2295
108. Bruyneel E.A., Storme G.A., Schallier D.C., et al. Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro. Eur J Cancer 29A (1993) 1958-1963
109. Berkovic D., Grundel O., Berkovic K., et al. Synergistic cytotoxic effects of ether phospholipid analogues and ionizing radiation in human carcinoma cells. Radiother Oncol 43 (1997) 293-301
110. Vink S.R., Lagerwerf S., Mesman E., et al. Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. Clin Cancer Res 12 (2006) 1615-1622
111. Rubel A., Handrick R., Lindner L.H., et al. The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiat Oncol 1 (2006) 6
112. Ruiter G.A., Verheij M., Zerp S.F., et al. Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int J Radiat Oncol Biol Phys 49 (2001) 415-419
113. Aoki H., Kang P.M., Hampe J., et al. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem 277 (2002) 10244-10250
114. Kharbanda S., Saxena S., Yoshida K., et al. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J Biol Chem 275 (2000) 322-327
115. Goillot E., Raingeaud J., Ranger A., et al. Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc Natl Acad Sci USA 94 (1997) 3302-3307
116. Verheij M., Bose R., Lin X.H., et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380 (1996) 75-79
117. Zanke B.W., Boudreau K., Rubie E., et al. The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat. Curr Biol 6 (1996) 606-613
118. Gajate C., Santos-Beneit A., Modolell M., et al. Involvement of c-Jun NH2-terminal kinase activation and c-Jun in the induction of apoptosis by the ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. Mol Pharmacol 53 (1998) 602-612
119. Handrick R., Rubel A., Faltin H., et al. Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling. Radiother Oncol 80 (2006) 199-206
120. de la Pena L., Burgan W.E., Carter D.J., et al. Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol Cancer Ther 5 (2006) 1504-1510
121. Vink S.R., Schellens J.H., Beijnen J.H., et al. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother Oncol 80 (2006) 207-213
122. van der Luit A.H., Budde M., Ruurs P., et al. Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J Biol Chem 277 (2002) 39541-39547
123. Berkovic D., Haase D., Hiddemann W., et al. Induction of resistance in the human leukemia cell line HL60 towards hexadecylphosphocholine and other ether phospholipid analogues. J Exp Ther Oncol 1 (1996) 368-375
124. Fleer E.A., Berkovic D., Grunwald U., et al. Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB. Eur J Cancer 32A (1996) 506-511
125. Dasmahapatra G.P., Didolkar P., Alley M.C., et al. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res 10 (2004) 5242-5252
126. Li X., Luwor R., Lu Y., et al. Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells. Oncogene 25 (2006) 525-535
127. Rahmani M., Reese E., Dai Y., et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 65 (2005) 2422-2432
128. Nyakern M., Cappellini A., Mantovani I., et al. Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther 5 (2006) 1559-1570
129. Momota H., Nerio E., and Holland E.C. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res 65 (2005) 7429-7435
130. Leighl NB, Warr D, Vandenberg T, et al. Phase II study of perifosine in metastatic or advanced breast cancer. San Antonio Breast Cancer Symposium 2004; abstract 1077.
131. Hedley D, Moore MJ, Hirte H, et al. A phase II trial of perifosine as second line therapy for advanced pancreatic cancer. A study of the Princess Margaret Hospital [PMH] phase II consortium. ASCO Annual Meeting Proceedings 2005; abstract 4166.
132. Chee KG, Lara PN, Longmate J, et al. The AKT inhibitor perifosine in biochemically recurrent, hormone sensitive prostate cancer (HSPC): A phase II California Cancer Consortium Trial. ASCO Annual Meeting Proceedings 2005; abstract 4642.